Kopf- und Neurozentrum, Klinik und Poliklinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany.
Stroke. 2011 May;42(5):1251-4. doi: 10.1161/STROKEAHA.110.600148. Epub 2011 Mar 17.
Stroke magnetic resonance imaging with perfusion and diffusion weighting has shown its potential to select patients likely to benefit from intravenous thrombolysis with tissue-type plasminogen activator (IV-tPA). We aimed to determine the predictors of favorable outcome in magnetic resonance imaging-selected, acute stroke patients treated with IV-tPA.
We analyzed the data of acute ischemic stroke patients from a prospective, multicenter, observational study of magnetic resonance imaging-based IV-tPA treatment initiated ≤6 hours from symptom onset. Neurologic deficit on admission was assessed by the National Institutes of Health Stroke Scale. Clinical outcome was assessed after 90 days according to the modified Rankin Scale. Favorable outcome was defined as a modified Rankin Scale score of 0 to 1. Patients were compared regarding baseline parameters. Multivariate regression analysis was used to identify predictors of favorable outcome.
Of 174 patients, 83 (48%) reached a favorable outcome. They were younger (median age, 62 versus 67 years; P=0.001), had a lower National Institutes of Health Stroke Scale score on admission (median, 11 versus 15; P<0.001), and had smaller diffusion-weighted imaging lesions (median, 12.9 versus 20 mL; P=0.001). Perfusion-weighted imaging lesion volumes and onset-to-treatment time were comparable between the groups. Age (P=0.017), National Institutes of Health Stroke Scale score on admission (P<0.001), and diffusion-weighted imaging lesion volume (P=0.047) were identified as independent predictors of favorable outcome.
A lower age, lower National Institutes of Health Stroke Scale score on admission, and smaller pretreatment diffusion-weighted imaging lesion volume were found to be associated with a favorable outcome after treatment with IV-tPA. Pretreatment perfusion lesion volume and onset-to-treatment time were not associated with outcome when patients were selected for IV-tPA by magnetic resonance imaging within 6 hours of symptom onset.
磁共振成像(MRI)联合灌注和弥散加权已显示出其在选择可能从组织型纤溶酶原激活物(tPA)静脉溶栓中获益的患者方面的潜力。本研究旨在确定经 MRI 选择的急性卒中患者接受 tPA 静脉溶栓治疗后良好结局的预测因素。
我们分析了一项前瞻性、多中心、观察性研究中接受 MRI 指导的 tPA 治疗的急性缺血性卒中患者的数据。该研究于症状发作后 6 小时内开始静脉溶栓治疗。入院时神经功能缺损采用国立卫生研究院卒中量表(NIHSS)评估。90 天后采用改良 Rankin 量表(mRS)评估临床结局。良好结局定义为 mRS 评分 0 至 1 分。比较了两组患者的基线参数。采用多变量回归分析确定良好结局的预测因素。
174 例患者中,83 例(48%)达到良好结局。与预后不良的患者相比,这些患者年龄较小(中位数 62 岁 vs 67 岁;P=0.001),入院 NIHSS 评分较低(中位数 11 分 vs 15 分;P<0.001),且弥散加权成像(DWI)病变较小(中位数 12.9 毫升 vs 20 毫升;P=0.001)。灌注加权成像(PWI)病变体积和发病至治疗时间在两组间无差异。年龄(P=0.017)、入院 NIHSS 评分(P<0.001)和 DWI 病变体积(P=0.047)是良好结局的独立预测因素。
发病 6 小时内行 MRI 筛选接受 tPA 静脉溶栓治疗的患者,年龄较小、入院 NIHSS 评分较低和 DWI 病变体积较小与治疗后良好结局相关。发病至治疗时间和 PWI 病变体积与结局无相关性。